Literature DB >> 23522788

Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients.

Catherine N Vu1, Raul Ruiz-Esponda, Eric Yang, Evelyn Chang, Baiba Gillard, Henry J Pownall, Ron C Hoogeveen, Ivonne Coraza, Ashok Balasubramanyam.   

Abstract

INTRODUCTION: Plasma triglycerides (TG) and HDL-C are inversely related in Metabolic Syndrome (MetS), due to exchange of VLDL-TG for HDL-cholesteryl esters catalyzed by cholesteryl ester transfer protein (CETP). We investigated the relationship of TG to HDL-C in highly-active antiretroviral drug (HAART)-treated HIV patients.
METHODS: Fasting plasma TG and HDL-C levels were compared in 179 hypertriglyceridemic HIV/HAART patients and 71 HIV-negative persons (31 normotriglyceridemic (NL) and 40 hypertriglyceridemic due to type IV hyperlipidemia (HTG)). CETP mass and activity were compared in 19 NL and 87 HIV/HAART subjects.
RESULTS: Among the three groups, a plot of HDL-C vs. TG gave similar slopes but significantly different y-intercepts (9.24±0.45, 8.16±0.54, 6.70±0.65, sqrt(HDL-C) for NL, HIV and HTG respectively; P<0.001); this difference persisted after adjusting HDL-C for TG, age, BMI, gender, glucose, CD4 count, viral load and HAART strata (7.18±0.20, 6.20±0.05 and 4.55±0.15 sqrt(HDL-C) for NL, HIV and HTG, respectively, P<0.001). CETP activity was not different between NL and HIV, but CETP mass was significantly higher in HIV (1.47±0.53 compared to 0.93±0.27μg/mL, P<0.0001), hence CETP specific activity was lower in HIV (22.67±13.46 compared to 28.46±8.24nmol/μg/h, P=0.001).
CONCLUSIONS: Dyslipidemic HIV/HAART patients have a distinctive HDL-C plasma concentration adjusted for TG. The weak inverse relationship between HDL-C and TG is not explained by altered total CETP activity; it could result from a non-CETP-dependent mechanism or a decrease in CETP function due to inhibitors of CETP activity in HIV patients' plasma.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23522788      PMCID: PMC3691339          DOI: 10.1016/j.metabol.2013.01.020

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  34 in total

1.  Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia.

Authors:  M Guérin; W Le Goff ; T S Lassel; A Van Tol ; G Steiner; M J Chapman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-02       Impact factor: 8.311

2.  A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

Authors:  T Saint-Marc; M Partisani; I Poizot-Martin; F Bruno; O Rouviere; J M Lang; J A Gastaut; J L Touraine
Journal:  AIDS       Date:  1999-09-10       Impact factor: 4.177

3.  Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity.

Authors:  T Gautier; D Masson; J P de Barros; A Athias; P Gambert; D Aunis; M H Metz-Boutigue; L Lagrost
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

4.  Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus.

Authors:  S D Niemeijer-Kanters; G M Dallinga-Thie; F C de Ruijter-Heijstek; A Algra; D W Erkelens; J D Banga; H Jansen
Journal:  Atherosclerosis       Date:  2001-05       Impact factor: 5.162

5.  Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome.

Authors:  Rajagopal V Sekhar; Farook Jahoor; Henry J Pownall; Khaleel Rehman; John Gaubatz; Dinakar Iyer; Ashok Balasubramanyam
Journal:  Am J Clin Nutr       Date:  2005-06       Impact factor: 7.045

6.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Authors:  A Carr; K Samaras; S Burton; M Law; J Freund; D J Chisholm; D A Cooper
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

7.  Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.

Authors:  Lisa J Ware; Akil G A Jackson; Stephen A Wootton; Graham C Burdge; John F Morlese; Graeme J Moyle; Alan A Jackson; Brian G Gazzard
Journal:  Br J Nutr       Date:  2009-06-01       Impact factor: 3.718

8.  Accelerated cholesteryl ester transfer in noninsulin-dependent diabetes mellitus.

Authors:  J D Bagdade; J T Lane; P V Subbaiah; M E Otto; M C Ritter
Journal:  Atherosclerosis       Date:  1993-12       Impact factor: 5.162

9.  HIV infection and high density lipoprotein metabolism.

Authors:  Honor Rose; Jennifer Hoy; Ian Woolley; Urbain Tchoua; Michael Bukrinsky; Anthony Dart; Dmitri Sviridov
Journal:  Atherosclerosis       Date:  2007-12-04       Impact factor: 5.162

10.  Lipid transfer inhibitor protein defines the participation of high density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP).

Authors:  Viktor M Paromov; Richard E Morton
Journal:  J Biol Chem       Date:  2003-08-07       Impact factor: 5.157

View more
  12 in total

Review 1.  Metabolic syndrome, diabetes, and cardiovascular risk in HIV.

Authors:  Linda M Nix; Phyllis C Tien
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

2.  HIV therapy, metabolic and cardiovascular health are associated with glomerular hyperfiltration among men with and without HIV infection.

Authors:  Derek K Ng; Lisa P Jacobson; Todd T Brown; Frank J Palella; Jeremy J Martinson; Robert Bolan; Edgar R Miller; George J Schwartz; Alison G Abraham; Michelle M Estrella
Journal:  AIDS       Date:  2014-01-28       Impact factor: 4.177

3.  Adapting Andersen's Behavioral Model of Health Service Use to Examine Risk Factors for Hypertension Among U.S. MSM.

Authors:  Sabina Hirshfield; Martin J Downing; Keith J Horvath; James A Swartz; Mary Ann Chiasson
Journal:  Am J Mens Health       Date:  2016-04-19

Review 4.  New Insights into the High-Density Lipoprotein Dilemma.

Authors:  Henry J Pownall; Antonio M Gotto
Journal:  Trends Endocrinol Metab       Date:  2015-12-07       Impact factor: 12.015

5.  Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects.

Authors:  Adelzon A Paula; Melissa Cn Falcão; Antonio G Pacheco
Journal:  AIDS Res Ther       Date:  2013-12-13       Impact factor: 2.250

Review 6.  Alcohol: a nutrient with multiple salutary effects.

Authors:  Henry J Pownall; Corina Rosales; Baiba K Gillard; Antonio M Gotto
Journal:  Nutrients       Date:  2015-03-18       Impact factor: 5.717

Review 7.  Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.

Authors:  Nicola Tarantino; Francesco Santoro; Luisa De Gennaro; Michele Correale; Francesca Guastafierro; Antonio Gaglione; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Vasc Health Risk Manag       Date:  2017-02-16

8.  Regulating Innate and Adaptive Immunity for Controlling SIV Infection by 25-Hydroxycholesterol.

Authors:  Tongjin Wu; Feng Ma; Xiuchang Ma; Weizhe Jia; Enxiang Pan; Genhong Cheng; Ling Chen; Caijun Sun
Journal:  Front Immunol       Date:  2018-11-21       Impact factor: 7.561

9.  Metabolically Healthy or Metabolically Unhealthy Obese HIV-Infected Patients: Mostly a Matter of Age?

Authors:  João Sérgio Neves; Vanessa Guerreiro; Davide Carvalho; Rosário Serrão; António Sarmento; Paula Freitas
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-16       Impact factor: 5.555

Review 10.  Comorbidities of HIV infection: role of Nef-induced impairment of cholesterol metabolism and lipid raft functionality.

Authors:  Dmitri Sviridov; Nigora Mukhamedova; Alexander A Makarov; Alexei Adzhubei; Michael Bukrinsky
Journal:  AIDS       Date:  2020-01-01       Impact factor: 4.632

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.